

COVID-19 Prevalence Study - Jefferson and Orleans Parishes

Amy Feehan, PhD

Daniel Fort, PhD, MPH

Julia Garcia-Diaz, MD, MSc, FACP, FIDSA

Eboni Price-Haywood, MD, MPH

Cruz Velasco, PhD

Eric Sapp, MDiv, MPP

Dawn Pevey, RN, BSN, MBA

Leonardo Seoane, MD, FACP

Introduction



Amy Feehan, PhD

Ochsner Health Clinical Infectious
Disease Research

Principal Investigator



Robert Hart, MD

Chief Medical Officer

Ochsner Health



Sandra Kemmerly, MD


System Medical Director
of Hospital Quality

Ochsner Health

Study Overview


- **Goal:** To determine the true spread of SARS-CoV-2 in Jefferson and Orleans Parishes.
- Recruited adult residents (18+) to represent every age, race, ethnicity and neighborhood.
- Allowed interested participants to volunteer on testnola.org and targeted specific demographics via community outreach and advertising.
- Those enrolled in the study received free COVID-19 (nasopharyngeal swab) and antibody tests (blood draw).
- **Tests from 2,640** residents from a pool of more than **25,000 volunteers** representative of the parish populations.
- Testing occurred in locations across both parishes between May 11 – May 15.

Disease Progression



Active COVID-19 Infection by Zip Code


Shedding by ZIP



*Has an infection now

Total Exposed to COVID-19 by Zip Code

Exposure by ZIP



***Has an infection now or has previously been infected**

Prevalence by Race

	Positive n (total)	Number of O/JP Residents ^a	Raw Prevalence % (CI)	Weighted Prevalence ^b % (CI)	Weighted Seroprevalence % (CI)	Presumed recovered ^c	Deaths as of May 16, 2020 ^a	IFR ^d % (CI)
Total	183 (2640)	825,057	6.9 (6.0,8.0)	7.8 (7.76,7.88)	6.86 (6.8,6.91)	56,578	925	1.63 (1.53,1.74)
White	79 (1607)	419,800	4.9 (3.9,6.1)	5.9 (5.78,5.93)	4.5 (4.44,4.58)	18,975	299	1.58 (1.41,1.77)
Black	90 (828)	356,925	10.9 (8.8,13.2)	10.3 (10.19,10.39)	9.8 (9.7,9.9)	34,973	600	1.72 (1.58,1.86)
Asian	9 (130)	29,740	6.9 (3.2,12.7)	6.4 (6.13,6.69)	5.5 (5.2,5.7)	1,629	10	0.61 (0.33,1.14) ^e
Native American	0 (14)	4,088	0	0	0	-	0	-
Pacific Islander	0 (3)	495	0	0	0	-	2	-
Multiracial /other	5 (58)	14,009	8.6 (2.9,19.0)	9.4 (8.96,9.94)	7.1 (6.7,7.6)	1,001	14	1.40 (0.83,2.36)
Hispanic ^f	18 (293)	86,289	6.1 (3.7,9.5)	7.5 (7.30, 7.65)	5.3 (5.16,5.46)	4,582	unknown	-

^a 2018 population estimates and deaths by race reported by ldh.la.gov

^b Census-weighted prevalence of PCR+ and/or IgG+ tests calculated to match 2018 demographics by Parish and then combined.

^c Number of residents multiplied by weighted seroprevalence (IgG+ tests).

^d Infection Fatality Rate (IFR) equals the number of deaths over presumed infections.


^e Significantly lower than white (p=0.0034), Black (p=0.0013) and multiracial (p=0.0467)

^f Hispanic ethnicity is a separate analysis and numbers were not subtracted from race. Hispanic deaths were not reported by the state as of May 16, 2020.

Key Findings – Prevalence Rates

- **7.8%** of Jefferson and Orleans Parish residents had been exposed to COVID-19 at the time of the study.
- It's presumed that more than **64,000 residents** have been infected in addition to those detected by state testing.
- Prevalence is higher among minorities, particularly Black residents
- **Infection Fatality Rate** (deaths/recovered *from our study*) is different than **Case Fatality Rate** (deaths/known cases *from state*)
 - IFR= 1.63%, CFR= 6%
 - IFR of the flu is 0.04-0.16%
 - IFR of COVID-19 in our population is **10-40x more deadly than the flu**


Positive Rates by Symptoms and Comorbidities




Anosmia (loss of smell and taste) associated with **17x** higher odds of testing positive.

Comorbidities did not influence whether someone caught the virus - they influence outcomes.

Disease Progression




Virus, Antibody and Symptoms



Age

Percent asymptomatic, comorbidity positive, and disease stage by age



Key Findings - Symptoms

- Any reported symptoms were associated with higher odds of testing positive.
- **75% of infectious people were asymptomatic.**
- **~40% of people never experience symptoms.**
- Whether someone was asymptomatic or symptomatic did not impact the amount of virus or antibody.
- Older people were more likely to be asymptomatic.

Takeaways for the Public

- Until a vaccine is developed, COVID-19 remains a significant risk in our community.
- Everyone must take action to reduce the spread of COVID-19.
- Symptoms are not always present when you are infectious – use caution and follow guidelines for social distancing and handwashing at all times.
- Review testing guidance to determine the appropriate time and place to get a COVID-19 test.
- Masks On!



Questions?
